Quantum Biopharma (QNTM) Change in Receivables (2019 - 2026)
Quantum Biopharma recorded quarterly Change in Receivables of $208524.0 in Q1 2026, up 309.15% quarter-over-quarter from -$99701.0 in Q4 2025, and down 47.05% year-over-year from $393843.0 in Q1 2025.
Quantum Biopharma's Change in Receivables history runs 8 years deep, the most recent figure standing at $208524.0 for Q1 2026.
- In Q1 2026, Change in Receivables fell 47.05% year-over-year to $208524.0; the TTM figure through Mar 2026 stood at $208524.0 (down 47.05% YoY), while the FY2025 annual figure was $231053.0, down 38.33% from the prior year.
- Change in Receivables came in at $208524.0 for Q1 2026 at Quantum Biopharma, up from -$99701.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $951503.0 in Q2 2022 to a low of -$270474.0 in Q4 2024.
- A 5-year average of $185150.1 and a median of $170611.0 in 2022 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables sank 1758.42% in 2024 and jumped 533.23% in 2025, its largest moves.
- Quantum Biopharma's Change in Receivables stood at -$49813.0 in 2022, then surged by 70.78% to -$14554.0 in 2023, then tumbled by 1758.42% to -$270474.0 in 2024, then surged by 63.14% to -$99701.0 in 2025, then soared by 309.15% to $208524.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $208524.0, -$99701.0, and $78300.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22,529.00 |
| Mar 31, 2026 | 22,529.00 |
| Dec 31, 2025 | -99,701.00 |
| Dec 31, 2025 | -99,701.00 |
| Sep 30, 2025 | 78,300.00 |
| Sep 30, 2025 | 78,300.00 |
| Jun 30, 2025 | 193,198.00 |
| Jun 30, 2025 | 193,198.00 |
| Mar 31, 2025 | 99,417.00 |
| Mar 31, 2025 | 99,417.00 |
| Dec 31, 2024 | -270,474.00 |
| Dec 31, 2024 | -270,474.00 |
| Sep 30, 2024 | 104,204.00 |
| Sep 30, 2024 | 104,204.00 |
| Jun 30, 2024 | 86,868.00 |
| Jun 30, 2024 | 86,868.00 |
| Mar 31, 2024 | 62,196.00 |
| Mar 31, 2024 | 62,196.00 |
| Dec 31, 2023 | -14,554.00 |
| Dec 31, 2023 | -14,554.00 |
| Sep 30, 2023 | 214,210.00 |
| Sep 30, 2023 | 214,210.00 |
| Jun 30, 2023 | 369,024.00 |
| Jun 30, 2023 | 369,024.00 |
| Mar 31, 2023 | 425,048.00 |
| Mar 31, 2023 | 425,048.00 |
| Dec 31, 2022 | -49,813.00 |
| Dec 31, 2022 | -49,813.00 |
| Sep 30, 2022 | 324,564.00 |
| Sep 30, 2022 | 324,564.00 |
| Jun 30, 2022 | 951,503.00 |
| Jun 30, 2022 | 951,503.00 |
| Mar 31, 2022 | 170,611.00 |
| Mar 31, 2022 | 170,611.00 |
| Dec 31, 2021 | 101,234.00 |
| Dec 31, 2021 | 101,234.00 |
| Sep 30, 2021 | 604,467.00 |
| Sep 30, 2021 | 604,467.00 |
| Jun 30, 2021 | 472,625.00 |
| Jun 30, 2021 | 472,625.00 |
| Mar 31, 2021 | 52,894.00 |
| Mar 31, 2021 | 52,894.00 |
| Dec 31, 2020 | 161,342.00 |
| Dec 31, 2020 | 161,342.00 |
| Sep 30, 2020 | 3.55 Mn |
| Sep 30, 2020 | 3.55 Mn |
| Jun 30, 2020 | 1.49 Mn |
| Jun 30, 2020 | 1.49 Mn |
| Dec 31, 2019 | 1.57 Mn |
| Dec 31, 2019 | 1.57 Mn |